Abstract
It is a common practice in drug discovery organizations to screen new chemical entities in order to predict future drug-drug interactions. For this purpose, there are two main assay strategies, one based on recombinant cytochrome P450 (rCYP) enzymes and fluorescent detection, and other on human liver microsomes (HLM) and liquid chromatography coupled to mass spectrometry. Many authors have reported a poor correlation between both technologies, giving rise to concerns about the usefulness of fluorometric methods for predicting drug-drug interactions. In this study, we investigated the role that compound aqueous kinetic solubility may play in this lack of correlation. We found that drug discovery compounds with unacceptable kinetic solubility, measured by a turbidimetric solutibility assay, tended to yield higher IC50 values in in vitro models based on human liver microsomes, whereas compounds with kinetic solubility values higher than 50 μM showed very similar IC50 values in both in vitro models. Our results show that the turbidimetric solubility assay is a useful tool to identify those discovery compounds that may require further investigation in order to avoid overlooking future drug-drug interactions.
Highlights
In the drug discovery process, it is important to determine possible drug-drug interactions of new drug candidates mediated by CYP450 inhibition
We found that drug discovery compounds with unacceptable kinetic solubility, measured by a turbidimetric solutibility assay, tended to yield higher IC50 values in in vitro models based on human liver microsomes, whereas compounds with kinetic solubility values higher than 50 μM showed very similar IC50 values in both in vitro models
The most widely accepted approach for in vitro evaluation of cytochrome P450 (CYP) inhibitory potential requires the use of hu man liver microsomes (HLM) as the source of enzyme, with “drug-like” substrates, using liquid chromatography coupled to mass spectrometry (LC-MS) for quantifying the enzymatic activity
Summary
In the drug discovery process, it is important to determine possible drug-drug interactions of new drug candidates mediated by CYP450 inhibition. The most widely accepted approach for in vitro evaluation of CYP inhibitory potential requires the use of hu man liver microsomes (HLM) as the source of enzyme, with “drug-like” substrates, using liquid chromatography coupled to mass spectrometry (LC-MS) for quantifying the enzymatic activity. This methodology is expensive and time-consuming, and does not deliver the high throughput typically required in the drug discovery process. Several high throughput methodologies have been developed using fluorogenic probe substrates and recombinant CYP450 enzymes (Miller et al, 2000)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have